Identification of DNA methylation of SOX9 in cervical cancer using methylated-CpG island recovery assay

Wu,Jian-Hong; Liang,Xue-Ai; Wu,Yu-Mei; Li,Feng-Shuang; Dai,Yin-Mei

doi:10.3892/or.2012.2077

Identification of DNA methylation of SOX9 in cervical cancer using methylated-CpG island recovery assay

Authors:
- Jian-Hong Wu
- Xue-Ai Liang
- Yu-Mei Wu
- Feng-Shuang Li
- Yin-Mei Dai
View Affiliations

Affiliations: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, P.R. China, Haidian Maternal and Child Health Hospital, Beijing 100080, P.R. China
Published online on: October 9, 2012 https://doi.org/10.3892/or.2012.2077
Pages: 125-132

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to identify novel methylation markers for cervical cancer screening and to test the clinical application of the most promising biomarker in cervical scrapings. Methylated-CpG island recovery assay-based microarray analysis was carried out on a discovery set consisting of cervical cancer tissue and normal cervical tissue to identify significantly hypermethylated genes. Five hundred and four CpG islands, corresponding to 378 genes, were differentially methylated between cervical cancer tissue and normal cervical tissue. Among them, 30 genes were significantly hypermethylated. Of the 30 genes, SOX9, PKLR and DLX4 were selected for further validation by direct bisulfite sequencing. The SOX9 gene revealed complete methylation in the cervical cancer tissue and complete non-methylation in the normal control tissue. A TaqMan-based real-time PCR assay was performed to detect the methylation levels of the SOX9 gene in 156 cervical scrapings, including 48 normal cervical scrapings, 30 scrapings with cervical intraepithelial neoplasia 1 (CIN1), 30 scrapings with CIN2-3 and 48 scrapings with squamous cell carcinoma (SCC). The methylation levels (methylation score) of the SOX9 gene increased significantly with the severity of cervical squamous lesions. The area under the receiver operating characteristic (ROC) curve (AUC) revealed that the methylation score of the SOX9 gene could be used to segregate SCC/CIN2-3 from CIN1/normal (AUC, 0.961; p=0.000). At the optimal cut-off value, a sensitivity of 92.3% and a specificity of 89.7% were obtained. In conclusion, SOX9 methylation is frequently involved in cervical carcinogenesis, and may provide a valuable molecular biomarker for early detection of cervical cancer.

View Figures

View References

1	Parkin DM, Pisani P and Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 80:827–841. 1999. View Article : Google Scholar : PubMed/NCBI
2	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar
3	Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG and Bulten J: Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol. 111:167–177. 2008. View Article : Google Scholar : PubMed/NCBI
4	Mayrand MH, Duarte-Franco E, Rodrigues I, et al: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 357:1579–1588. 2007. View Article : Google Scholar : PubMed/NCBI
5	Cuzick J, Szarewski A, Cubie H, et al: Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 362:1871–1876. 2003. View Article : Google Scholar : PubMed/NCBI
6	Wright TJ, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ and Solomon D: 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 197:340–345. 2007. View Article : Google Scholar
7	Castle PE, Schiffman M, Wheeler CM and Solomon D: Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 113:18–25. 2009. View Article : Google Scholar : PubMed/NCBI
8	McCredie MR, Sharples KJ, Paul C, et al: Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 9:425–434. 2008. View Article : Google Scholar : PubMed/NCBI
9	Pretorius RG, Peterson P, Azizi F and Burchette RJ: Subsequent risk and presentation of cervical intraepithelial neoplasia (CIN) 3 or cancer after a colposcopic diagnosis of CIN 1 or less. Am J Obstet Gynecol. 195:1260–1265. 2006. View Article : Google Scholar : PubMed/NCBI
10	Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res. 61:3225–3229. 2001.PubMed/NCBI
11	Shivapurkar N, Sherman ME, Stastny V, et al: Evaluation of candidate methylation markers to detect cervical neoplasia. Gynecol Oncol. 107:549–553. 2007. View Article : Google Scholar : PubMed/NCBI
12	Wentzensen N, Sherman ME, Schiffman M and Wang SS: Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol. 112:293–299. 2009. View Article : Google Scholar : PubMed/NCBI
13	Iliopoulos D, Oikonomou P, Messinis I and Tsezou A: Correlation of promoter hypermethylation in hTERT, DAPK and MGMT genes with cervical oncogenesis progression. Oncol Rep. 22:199–204. 2009.PubMed/NCBI
14	Feng Q, Balasubramanian A, Hawes SE, et al: Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst. 97:273–282. 2005. View Article : Google Scholar : PubMed/NCBI
15	Wisman GB, Nijhuis ER, Hoque MO, et al: Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer. 119:1908–1914. 2006. View Article : Google Scholar : PubMed/NCBI
16	Jung S, Yi L, Jeong D, et al: The role of ADCYAP1, adenylate cyclase activating polypeptide 1, as a methylation biomarker for the early detection of cervical cancer. Oncol Rep. 25:245–252. 2011.PubMed/NCBI
17	Lai HC, Lin YW, Huang TH, et al: Identification of novel DNA methylation markers in cervical cancer. Int J Cancer. 123:161–167. 2008. View Article : Google Scholar : PubMed/NCBI
18	Sova P, Feng Q, Geiss G, et al: Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev. 15:114–123. 2006. View Article : Google Scholar : PubMed/NCBI
19	Wang SS, Smiraglia DJ, Wu YZ, et al: Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning. Cancer Res. 68:2489–2497. 2008. View Article : Google Scholar : PubMed/NCBI
20	Rauch TA and Pfeifer GP: The MIRA method for DNA methylation analysis. Methods Mol Biol. 507:65–75. 2009. View Article : Google Scholar : PubMed/NCBI
21	Martens JW, Nimmrich I, Koenig T, et al: Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res. 65:4101–4117. 2005. View Article : Google Scholar : PubMed/NCBI
22	Huang TH, Lai HC, Liu HW, et al: Quantitative analysis of methylation status of the PAX1 gene for detection of cervical cancer. Int J Gynecol Cancer. 20:513–519. 2010. View Article : Google Scholar : PubMed/NCBI
23	Missaoui N, Hmissa S, Dante R and Frappart L: Global DNA methylation in precancerous and cancerous lesions of the uterine cervix. Asian Pac J Cancer Prev. 11:1741–1744. 2010.PubMed/NCBI
24	Nephew KP: What will it take to obtain DNA methylation markers for early cervical cancer detection? Gynecol Oncol. 112:291–292. 2009. View Article : Google Scholar : PubMed/NCBI
25	Apostolidou S, Hadwin R, Burnell M, et al: DNA methylation analysis in liquid-based cytology for cervical cancer screening. Int J Cancer. 125:2995–3002. 2009. View Article : Google Scholar : PubMed/NCBI
26	Kim JH, Choi YD, Lee JS, Lee JH, Nam JH and Choi C: Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. Gynecol Oncol. 116:99–104. 2010. View Article : Google Scholar
27	Lim EH, Ng SL, Li JL, et al: Cervical dysplasia: assessing methylation status (Methylight) of CCNA1, DAPK1, HS3ST2, PAX1 and TFPI2 to improve diagnostic accuracy. Gynecol Oncol. 119:225–231. 2010. View Article : Google Scholar : PubMed/NCBI
28	Eijsink JJ, Lendvai A, Deregowski V, et al: A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer. 130:1861–1869. 2012. View Article : Google Scholar : PubMed/NCBI
29	Eijsink JJ, Yang N, Lendvai A, et al: Detection of cervical neoplasia by DNA methylation analysis in cervico-vaginal lavages, a feasibility study. Gynecol Oncol. 120:280–283. 2011. View Article : Google Scholar : PubMed/NCBI
30	Glockner SC, Dhir M, Yi JM, et al: Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 69:4691–4699. 2009. View Article : Google Scholar : PubMed/NCBI
31	Lefebvre V, Dumitriu B, Penzo-Mendez A, Han Y and Pallavi B: Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors. Int J Biochem Cell Biol. 39:2195–2214. 2007. View Article : Google Scholar : PubMed/NCBI
32	Kent J, Wheatley SC, Andrews JE, Sinclair AH and Koopman P: A male-specific role for SOX9 in vertebrate sex determination. Development. 122:2813–2822. 1996.PubMed/NCBI
33	Soderstrom M, Bohling T, Ekfors T, Nelimarkka L, Aro HT and Vuorio E: Molecular profiling of human chondrosarcomas for matrix production and cancer markers. Int J Cancer. 100:144–151. 2002. View Article : Google Scholar : PubMed/NCBI
34	Stolt CC, Lommes P, Sock E, Chaboissier MC, Schedl A and Wegner M: The Sox9 transcription factor determines glial fate choice in the developing spinal cord. Genes Dev. 17:1677–1689. 2003. View Article : Google Scholar : PubMed/NCBI
35	Afonja O, Raaka BM, Huang A, et al: RAR agonists stimulate SOX9 gene expression in breast cancer cell lines: evidence for a role in retinoid-mediated growth inhibition. Oncogene. 21:7850–7860. 2002. View Article : Google Scholar : PubMed/NCBI
36	Drivdahl R, Haugk KH, Sprenger CC, Nelson PS, Tennant MK and Plymate SR: Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9. Oncogene. 23:4584–4593. 2004. View Article : Google Scholar : PubMed/NCBI
37	Enjuanes A, Fernandez V, Hernandez L, et al: Identification of methylated genes associated with aggressive clinicopathological features in mantle cell lymphoma. PLoS One. 6:e197362011. View Article : Google Scholar : PubMed/NCBI
38	Aleman A, Adrien L, Lopez-Serra L, et al: Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer. 98:466–473. 2008. View Article : Google Scholar : PubMed/NCBI
39	Bennett LB, Schnabel JL, Kelchen JM, et al: DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma. Genes Chromosomes Cancer. 48:828–841. 2009. View Article : Google Scholar : PubMed/NCBI
40	Chakravarty G, Moroz K, Makridakis NM, et al: Prognostic significance of cytoplasmic SOX9 in invasive ductal carcinoma and metastatic breast cancer. Exp Biol Med. 236:145–155. 2011. View Article : Google Scholar : PubMed/NCBI
41	Sun M, Uozaki H, Hino R, et al: SOX9 expression and its methylation status in gastric cancer. Virchows Arch. 460:271–279. 2012. View Article : Google Scholar : PubMed/NCBI
42	Wang KH, Liu HW, Lin SR, Ding DC and Chu TY: Field methylation silencing of the protocadherin 10 gene in cervical carcinogenesis as a potential specific diagnostic test from cervical scrapings. Cancer Sci. 100:2175–2180. 2009. View Article : Google Scholar : PubMed/NCBI